10-Q: Encision Inc. Reports Mixed Results in Q2 2025, Focuses on AEM Technology Growth

Encision Inc. reports a net loss for the quarter ended September 30, 2024, despite increased service revenue and efforts to expand market awareness of its AEM technology.

Summary

• Encision Inc. reported a net loss of $170,262 for the three months ended September 30, 2024, compared to a net loss of $7,529 for the same period in 2023.
• The company's net product revenue decreased by 6% to $1,653,820 for the quarter, while net service revenue increased to $101,568.
• Gross profit decreased by 4% to $828,482, impacted by a non-cash increase to inventory reserves of $81,603.
• Operating expenses increased, with sales and marketing up 18% and research and development up 54%.
• For the six months ended September 30, 2024, the net loss was $148,222, compared to a net loss of $147,983 for the same period in 2023.
• The company's cash position increased by $187,505 to $230,014, primarily due to cash generated from operations and borrowings.
• Working capital decreased to $1,142,362 from $1,206,252 at the end of the previous fiscal year.
• The company has an accumulated deficit of $22,693,269 as of September 30, 2024.
• Encision is focused on expanding the market for its AEM technology and improving sales efficiency.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive aspects like increased service revenue and cash generation, but the significant net loss, decreased product revenue, and the need for potential future capital raises weigh heavily on the overall sentiment. The company is facing challenges in its core business and has identified material weaknesses in internal controls.

Positives

• Net service revenue increased for both the three and six month periods ended September 30, 2024.
• The company generated $192,699 of cash from operating activities during the six months ended September 30, 2024.
• The company's cash balance increased by $187,505 in the six months ended September 30, 2024.
• Gross profit on product net revenue as a percentage of sales was 52% for the six months ended September 30, 2024, up from 50% for the same period in 2023.
• The company is actively working to remediate material weaknesses in internal controls.

Negatives

• The company reported a net loss of $170,262 for the three months ended September 30, 2024, a significant increase from the $7,529 loss in the same period of 2023.
• Net product revenue decreased by 6% for the quarter and 4% for the six months ended September 30, 2024.
• Gross profit decreased by 4% for the quarter ended September 30, 2024, due to a non-cash increase to inventory reserves.
• Sales and marketing expenses increased by 18% for the quarter ended September 30, 2024.
• Research and development expenses increased by 54% for the quarter ended September 30, 2024.
• The company's working capital decreased by $64,890 from March 31, 2024.
• The company has an accumulated deficit of $22,693,269 as of September 30, 2024.

Risks

• The company has an accumulated deficit of $22,693,269 and may require additional capital in the future.
• The company is dependent on the success of its AEM technology and may face challenges if surgeons prefer other instruments.
• The company's operating results may fluctuate due to product sales mix, sales volume, and service revenue.
• The company is subject to regulation by the FDA and must maintain compliance.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's net operating loss carryforwards may be limited by changes in ownership interests.
• The omission or delay of elective surgeries would negatively impact the extent and timing of revenue growth.

Future Outlook

The company aims to increase sales of its AEM products, expand market awareness, and maximize the number of hospital and surgery center accounts switching to AEM instruments. They also plan to develop next-generation products and explore overseas markets and licensing opportunities.

Management Comments

• Management is developing plans to ensure that the Company has the working capital necessary to fund operations.
• Management concludes that it is probable that cash resources and line of credit will be sufficient to meet cash requirements for twelve months from the issuance of the unaudited condensed financial statements.
• The company increased the pricing on products to mitigate higher material costs.
• The company believes that the unique performance of the AEM technology and our breadth of independent endorsements provide an opportunity for continued market share growth.
• The company's objectives for the remainder of fiscal year 2025 are to optimize sales execution, to expand market awareness of the AEM technology and to maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers.

Industry Context

The report highlights the increasing focus on patient safety in minimally-invasive surgery, which aligns with industry trends and regulatory pressures. The company's AEM technology addresses a specific risk in laparoscopic surgery, which is a growing market segment. The company is also impacted by the broader medical device industry and the volume of elective surgeries.

Comparison to Industry Standards

• Encision's focus on patient safety through its AEM technology aligns with the broader industry trend of reducing hospital-acquired conditions, similar to initiatives by companies like Medtronic and Johnson & Johnson.
• The company's reliance on a line of credit and loans for funding is not uncommon for smaller medical device companies, but it contrasts with larger, more established players that have access to more diverse capital sources.
• The company's gross margins of around 50% are within the range of other medical device companies, but the fluctuations due to inventory reserves highlight the challenges of managing costs in a competitive market.
• The company's research and development expenses, while increasing, are still relatively low compared to larger companies that invest heavily in innovation, such as Intuitive Surgical.
• The company's sales and marketing expenses are increasing, which is typical for companies trying to expand market share, similar to strategies employed by smaller medical device companies trying to compete with larger players.

Corporate Governance

Legal Proceedings

• The company is not currently aware of any legal proceedings or claims that it believes will have a material adverse effect on its business, financial condition, or results of operations.

Related Party Transactions

• The company paid consulting fees of $15,043 and $27,670 to an entity owned by one of the board members during the three and six months ended September 30, 2024, respectively.

Stakeholder Impact

• Shareholders may be concerned about the company's net losses and the potential need for additional capital.
• Employees may be affected by the company's efforts to improve efficiency and reduce costs.
• Customers, primarily hospitals and surgery centers, may benefit from the company's AEM technology, which aims to improve patient safety.
• Suppliers may be impacted by the company's efforts to manage inventory and reduce costs.
• Creditors may be concerned about the company's financial performance and its ability to repay its debts.

Next Steps

• The company plans to optimize sales execution.
• The company plans to expand market awareness of the AEM technology.
• The company plans to maximize the number of additional hospital and surgery center accounts switching to AEM instruments while retaining existing customers.
• The company plans to develop next generation versions of the AEM product line.
• The company plans to explore overseas markets to assess opportunities for sales growth internationally.
• The company intends to explore opportunities to capitalize on its proven AEM technology via licensing arrangements and strategic alliances.

Key Dates

Keywords

AEM technology, medical devices, electrosurgery, laparoscopic surgery, surgical instruments, patient safety, revenue, gross profit, operating expenses, net loss, financial results, internal controls